deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01979276

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (Romi Poma)

A Phase I/II Study of Pomalidomide (CC-4047®), Dexamethasone and Romidepsin in Patients With Relapsed or Refractory Multiple Myeloma (Romi Poma)

Sponsor: Celgene Corporation

Conditions Multiple Myeloma
Interventions Dexamethasone Romidepsin pomalidomide
Updated 10 times since 2017 Last updated: May 31, 2018 Started: Nov 30, 2013 Primary completion: Oct 31, 2016 Completion: Oct 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

this study was terminated due to losing financial support, and enrollment challenges

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

Listed as NCT01979276, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshotCompleted~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotTerminated~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotTerminated~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jul 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Jun 2018 — Jul 2018 [monthly]

    Terminated PHASE1_PHASE2

  3. Feb 2018 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  4. Feb 2017 — Feb 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations